Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG.
Jonasch E, et al.
Cancer J. 2000 May-Jun;6(3):139-45.
Cancer J. 2000.
PMID: 10882328
Clinical Trial.
Hepatotoxicity was evident in 39 (97.5%) patients, and 26 (65%) experienced grade 3 to 4 hepatotoxicity. Three patients (7.5%) experienced mild renal toxicity. At a median follow-up of 27 months from initiation of therapy, there have been 19 relapses (47.5% disease-free su …
Hepatotoxicity was evident in 39 (97.5%) patients, and 26 (65%) experienced grade 3 to 4 hepatotoxicity. Three patients (7.5%) experienced m …